Cutaneous lupus erythematosus (LE) is an autoimmune disease. The most common clinical forms are acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE) and discoid LE (DLE). Cutaneous LE, mainly ACLE, can be the first sign of systemic LE (SLE). DLE and SCLE are less associated with development of SLE, however, up to 85% of patients with SLE have cutaneous manifestations. The aetiology is multifactorial. Drugs such as proton pump inhibitors can induce SCLE, while UV-light and smoking can worsen the lesions. Treatment includes preventive strategies in addition to topical steroids and systemic hydroxychloroquine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- Cutaneous lupus erythematosus (CLE) is a skin-related manifestation of lupus erythematosus, classified into subtypes (acute, subacute, chronic) based on clinical characteristics and lab findings.
- Traditional treatments include topical corticosteroids and antimalarial drugs, but new immunomodulatory therapies, particularly Janus kinase (JAK) inhibitors, are emerging options.
- The review highlights the importance of understanding the JAK/STAT signaling pathway in CLE management and calls for more research on the safety and effectiveness of JAK inhibitors for autoimmune disease treatment.
Subtype and Racial Erythema Variation for Cutaneous Lupus Trials.
JAMA Dermatol
December 2024
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania.
Article Synopsis
- Regulatory guidance on disease outcome measures is crucial for improving clinical trials for cutaneous lupus erythematosus (CLE) and increasing participant diversity.
- A study of 377 CLE patients analyzed erythema variations across different subtypes and racial/ethnic groups to see how these differences impact eligibility for trials.
- Results showed significant erythema differences among CLE subtypes and among racial/ethnic groups, particularly with SCLE and hypertrophic CCLE being primarily classified as red.
Monoclonal Antibodies for the Management of Cutaneous Lupus Erythematosus: An Update on the Current Treatment Landscape.
Clin Exp Dermatol
September 2024
Department of Dermatology, UTHealth McGovern Medical School, Houston, TX, USA.
Article Synopsis
- Cutaneous lupus erythematosus (CLE) is an autoimmune disease that primarily affects the skin, divided into three categories: acute, subacute, and chronic.
- Treatment strategies for CLE involve patient education, medication regimens, and various therapies such as corticosteroids and immunomodulators, but currently, no biologic drugs are specifically approved for CLE.
- Research is ongoing into monoclonal antibodies (mAbs) like belimumab and anifrolumab that have been approved for other lupus conditions, with potential new mAbs being investigated to improve treatment options for CLE patients.
The role of TNF-α as a potential marker for acute cutaneous lupus erythematosus in patients with systemic lupus erythematosus.
J Dermatol
November 2024
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
Acute cutaneous lupus erythematosus (ACLE) is closely associated with systemic symptoms in systemic lupus erythematosus (SLE). This study aimed to identify potential biomarkers for ACLE and explore their association with SLE to enable early prediction of ACLE and identify potential treatment targets for the future. In total, 185 SLE-diagnosed patients were enrolled and categorized into two groups: those with ACLE and those without cutaneous involvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!